B of A Securities Initiates Coverage On Kanzhun with Neutral Rating, Announces Price Target of $74

Kanzhun Eyes Brazil, Argentina And Vietnam For Growth

The recruitment app operator’s revenue has slowed steadily over the last three years as it solidifies its dominant position in China image credit: Bamboo Works Key Takeaways: Kanzhun’s revenue grew 14.1%

Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Kanzhun shares are trading higher after the company reported better-than-expected Q2 EPS results.